Menu Search
Equities

Oxford Biomedica PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
OXOA:STU

Oxford Biomedica PLC

Actions
  • Price (EUR)9.25
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+94.33%
  • Beta3.0186
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. The Company is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. Its AAV platform, which offers a proprietary plug and play dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.

  • Revenue in GBP (TTM)151.21m
  • Net income in GBP-37.07m
  • Incorporated1996
  • Employees900.00
  • Location
    Oxford Biomedica PLCWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
  • Phone+44 186 578 3000
  • Fax+44 186 578 3001
  • Websitehttps://www.oxb.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		OXB:LSE since
announced		Transaction
value
RTP Operating LLC-Gene Therapy Viral Vector Manufacturing FacilityDeal completed07 Oct 202507 Oct 2025Deal completed27.00%4.50m
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.